Clinical trial
A Study of ALT-801 in Patients With Relapsed or Refractory Multiple Myeloma
Name
CA-ALT-801-01-11
Description
This is a Phase Ib/II, open-label, multi-center and competitive enrollment study of ALT-801 in patients who have relapsed or refractory multiple myeloma.
Trial arms
Trial start
2012-08-14
Estimated PCD
2015-09-09
Trial end
2015-09-09
Status
Terminated
Phase
Early phase I
Treatment
ALT-801
Intravenous infusion; 2 treatment cycles: on day 1, 3, 8, and 15 of each cycle
Arms:
ALT-801 0.04mg/kg, ALT-801 0.06mg/kg
Other names:
c264scTCR-IL2
Size
6
Primary endpoint
Number of Participants With Treatment-Related Adverse Events
7 weeks
Eligibility criteria
ENTRY CRITERIA:
DISEASE CHARATERISTICS:
* Confirmed diagnosis of relapsed/refractory multiple myeloma after treatment with at least two different previous regimens.
* Refractory disease is defined as progressive disease while on therapy or progression within 60 days of therapy.
* Progressive disease is defined by a 25% increase from the lowest response value in specified tests.
* Measurable disease as defined by at least one of the following:
* Serum M-protein ≥ 1g/dL (for IgG, IgM) or 0.5 g/dL (for IgA)
* Urine M-protein ≥ 200mg/24hours
* Serum free light chains ≥ 10 mg/dL and abnormal kappa/lambda ratio
PRIOR/CONCURRENT THERAPY:
* No anti-myeloma treatments within 28 days before the start of study treatment.
* Must have recovered from side effects of prior treatments.
PATIENT CHARACTERISTICS:
Age
• ≥ 18 years
Performance Status
• ECOG 0, 1, or 2
Bone Marrow Reserve
* Absolute neutrophil count (AGC/ANC) ≥ 1,000/uL
* Platelets ≥ 30,000/uL
* Hemoglobin ≥ 8g/dL
Renal Function
• Glomerular Filtration Rate (GFR) \> 45mL/min/1.73m\^2
Hepatic Function
* Total bilirubin ≤ 2.0 X ULN
* AST, ALT, ALP ≤ 3.0 X ULN, or ≤ 5.0 X ULN (if liver metastases exist)
Cardiovascular
* No congestive heart failure \< 6 months
* No unstable angina pectoris \< 6 months
* No myocardial infarction \< 6 months
* No history of ventricular arrhythmias
* No history of supraventricular arrhythmias
* No NYHA Class \> II CHF
* Normal Transthoracic Echocardiogram (TTE) is required for patients with history of EKG abnormalities, CHF, coronary artery disease or other cardiac disease, or with a history of having received adriamycin or doxorubicin
* Patients with a left ventricular ejection fraction (LVEF) of less than 50% will be excluded from study entry
Pulmonary
• Normal clinical assessment of pulmonary function
Other
* Negative serum pregnancy test if female and of childbearing potential
* Women who are not pregnant or nursing
* Subjects, both females and males, with reproductive potential must agree to use effective contraceptive measures for the duration of the study
* No known autoimmune disease other than corrected hypothyroidism
* No known prior organ allograft or allogeneic transplantation
* Not HIV positive
* No history or evidence of uncontrollable CNS disease
* No psychiatric illness/social situation
* No other illness that in the opinion of the investigator would exclude the subject from participating in the study
* Must provide informed consent and HIPPA authorization and agree to comply with all protocol-specified procedures and follow-up evaluations
* Active systemic infection requiring parenteral antibiotic therapy.
* No ongoing chronic systemic steroid therapy required.
Protocol
{'studyType': 'INTERVENTIONAL', 'phases': ['PHASE1', 'PHASE2'], 'designInfo': {'allocation': 'NON_RANDOMIZED', 'interventionModel': 'SINGLE_GROUP', 'primaryPurpose': 'TREATMENT', 'maskingInfo': {'masking': 'NONE'}}, 'enrollmentInfo': {'count': 6, 'type': 'ACTUAL'}}
Updated at
2024-06-18
1 organization
1 product
1 indication
Organization
Altor BioScienceProduct
ALT-801Indication
Multiple Myeloma